India, April 15 -- PDS Biotechnology Corporation (PDSB) announced positive interim Phase 2 results from Stage 1 of an NCI-led trial evaluating its tumor-targeted IL-12 immunocytokine, PDS01ADC, in patients with metastatic colorectal cancer (mCRC).
The study focused on patients with microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal liver metastases- a group that makes up the majority of mCRC cases and has historically shown poor response to immune checkpoint inhibitors.
Key findings from the nine-patient cohort included:
-Objective response rate (ORR): 77.8% at six months, compared with 35% in a parallel trial without PDS01ADC.
-Two-year survival rate: Approximately 85%, versus approximately 40% in parallel tria...